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Abstract
A hallmark of Alzheimer’s disease (AD) is the accumulation of extracellular amyloid-β (Aβ)
plaques in the brains of patients. N-terminally truncated pyroglutamate-modified Aβ (pEAβ)
has been described as a major compound of Aβ species in senile plaques. pEAβ is more
resistant to degradation, shows higher toxicity and has increased aggregation propensity
and β-sheet stabilization compared to non-modified Aβ. Here we characterized recombi-
nant pEAβ(3–40) in aqueous trifluoroethanol (TFE) solution regarding its aggregation pro-
pensity and structural changes in comparison to its non-pyroglutamate-modified variant Aβ
(1–40). Secondary structure analysis by circular dichroism spectroscopy suggests that
pEAβ(3–40) shows an increased tendency to form β-sheet-rich structures in 20% TFE con-
taining solutions where Aβ(1–40) forms α-helices. Aggregation kinetics of pEAβ(3–40) in
the presence of 20% TFE monitored by thioflavin-T (ThT) assay showed a typical sigmoidal
aggregation in contrast to Aβ(1–40), which lacks ThT positive structures under the same
conditions. Transmission electron microscopy confirms that pEAβ(3–40) aggregated to
large fibrils and high molecular weight aggregates in spite of the presence of the helix stabi-
lizing co-solvent TFE. High resolution NMR spectroscopy of recombinantly produced and
uniformly isotope labeled [U-15N]-pEAβ(3–40) in TFE containing solutions indicates that the
pyroglutamate formation affects significantly the N-terminal region, which in turn leads to
decreased monomer stability and increased aggregation propensity.
Introduction
The pathology of Alzheimer’s disease (AD) is characterized by the presence of intracellular
neurofibrillary tangles consisting of accumulated hyperphosphorylated tau protein and extra-
cellular plaques containing amyloid-β (Aβ) as major component [1, 2]. Aβ is derived by
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processing of the amyloid precursor protein by β- and γ-secretases [3, 4]. Multiple possible
cleavage positions of γ-secretase combined with various posttranslational modifications of the
cleaved products result in different Aβ isoforms with heterogeneity in length as well as N- and
C-terminal sequences [5, 6]. Pyroglutamate-modified Aβ (pEAβ) peptides have been reported
to be the dominant component of all N-terminal truncated Aβ variants in AD plaques as up to
20% of the total Aβ are pEAβ variants [7–9]. pEAβ deposits in the brains of presymptomatic
AD patients [10] and was shown to play a dominant role in plaque formation and to provoke
neurodegeneration in mouse models [11, 12]. Formation of pEAβ is based on N-terminal trun-
cation leading to N-terminal E3 or E11 and subsequent cyclization of the accessible E amino
group with the side chain carboxy group leading to pyroglutamate. In vivo it was suggested the
cyclization is catalyzed by the enzyme glutaminyl cyclase [13, 14]. pEAβ starting at position 3
(pEAβ(3-x)) represents the major fraction of N-pyroglutamate modified Aβ species in intracel-
lular, extracellular and vascular accumulations in AD brains [15–18]. The cumulative deposi-
tion of pEAβ in AD brains coincides with increased protease-stability since the pyroglutamate
modified N-terminus is inaccessible to aminopeptidases [19, 20]. The loss of two negative char-
ges (side chain carboxyl groups of D1 and E3) and one positive charge (E3 amino group) at
physiological pH result in higher hydrophobicity of pEAβ(3-x) [19, 21]. Aggregation of pEAβ
(3-x) is up to 250-fold accelerated [22] and its neurotoxicity is enhanced [23, 24] when com-
pared with the corresponding wild type Aβ species independent of the C-terminal length.
Structural analysis of pEAβmonomers is essential to uncover its aggregation mechanism
and to reveal, why it is more prone to self-assembly than Aβ wild type. In a previous NMR
study, we analyzed pEAβ(3–40) in aqueous buffer conditions at neutral pH and compared it
with given Aβ(1–40) data [25]. Most chemical shifts were nearly identical except of the very N-
terminal region and both peptides were shown to be unstructured.
Since structural studies of Aβ peptides are often limited due to their high aggregation ten-
dency, solvent conditions need to be carefully chosen. α-helical Aβmonomers are predomi-
nantly formed in micelles [26], hexafluoroisopropanol (HFIP)/water [27] and
2,2,2-trifluoroethanol (TFE)/water [28] mixtures. In a previous NMR study we compared
pEAβ(3–40) with Aβ(1–40), both chemically synthesized with natural carbon and nitrogen iso-
tope abundance, in aqueous solution containing 40% TFE [29]. The results indicated that both
Aβ isoforms formed α-helical structures in two regions (aa 14–22 and aa 30–36) connected by
a flexible and disordered linker. However, pEAβ(3–40) exhibited a decreased helix propensity
in agreement with its higher hydrophobicity and faster aggregation kinetics.
Here, we analyzed the solvent conditions for the transition of pEAβ(3–40) from TFE-
induced α-helices to β-sheets by gradually lowering the TFE concentrations. We expand the
data by investigations of recombinantly produced [U-15N]-pEAβ(3–40) regarding structure
and aggregation in 20% TFE, where Aβ(1–40) is still in a predominantly α-helical monomeric
state, while pEAβ(3–40) forms a β-sheet dominated secondary structure, starts to aggregate
and forms large fibrils.
Materials and Methods
Peptides and sample preparation
Expression and purification of uniformly isotope labeled [U-15N]-pEAβ(3–40) and [U-15N]-
Aβ(1–40) as well as non-labeled pEAβ(3–40) were performed as described recently [25, 30].
Synthetic non-labeled Aβ(1–40) was purchased from Bachem (Heidelberg, Germany). Samples
were prepared in Protein LowBinding tubes (Eppendorf AG, 230 Hamburg, Germany). The Aβ
peptides were dissolved in HFIP (1,1,1,3,3,3,-hexafluoro-2-propanol, Sigma-Aldrich,
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Hannover, Germany) and monomerized for 3 days at room temperature. Samples were lyophi-
lized and stored at -20°C.
CD spectroscopy
Lyophilized peptides were dissolved in aqueous buffer containing different TFE concentrations
(20–25% TFE in 50 mM potassium phosphate, pH 2.8) to a final concentration of 25 μM. UV
CDmeasurements were performed in 1 mm path-length cuvettes at 20°C. CD spectra were
recorded on a Jasco J-1100 spectropolarimeter from 260 to 187 nm with 0.5 nm step size, 50
nm/min scan speed, 1 nm bandwidth and 10 scans per sample. Background correction was per-
formed by subtraction of corresponding buffer spectra.
ThT assay
Lyophilized peptides were dissolved to a final concentration of 25 μM in buffer (20–25% TFE
in 50 mM potassium phosphate, pH 2.8) containing 10 μMThT. Aggregation assays were per-
formed in black non-binding 96-well plates (Sigma-Aldrich, Germany) at 20°C with a total vol-
ume of 100 μl per well. Each reaction was performed fivefold and background corrected by
subtraction of the buffer control. Fluorescence was monitored in 10 min steps using a micro-
plate reader (PolarStar Optima, BMG, Offenburg, Germany) with 440 excitation and 492 nm
emission filters, respectively, in bottom-read mode. Wells were shaken 30°s prior to
measurement.
TEMmicroscopy
Lyophilized pEAβ(3–40) was dissolved in aqueous buffer (20% TFE in 50 mM potassium phos-
phate, pH 2.8) and incubated for five days at 20°C. Fibrils were absorbed on formval/carbon
coated copper grids (S162, Plano, Wetzlar, Germany) for 5 min and washed with water. Negative
staining was performed by incubation with 1% (w/v) uranylacetate for 1 min. Images were taken
with a Libra 120 transmission electron microscope (Zeiss, Oberkochen, Germany) at 120 kV.
NMR spectroscopy
Lyophilized [U-15N]-pEAβ(3–40) and [U-15N]-Aβ(1–40) were directly dissolved in 100% TFE-
d2-OH and diluted with 50 mM potassium phosphate, pH 2.8 to a final concentration of
25 μM peptide in 20% TFE. NMR spectra were acquired using a TXI- or QCI-cryoprobe
equipped Bruker Avance III HD 600 MHz spectrometer. 1H,15N-HSQC correlation spectra
were recorded according to standard Bruker pulse-sequences [31–33]. 1HN and
15N Backbone
resonance assignments in 30% TFE were obtained by using BEST-TROSY (BT) HNCA+-
optimized pulse sequences [34, 35]. Resonance assignments of spectra recorded at 30% TFE
concentration were transferred to the spectrum recorded at 20% TFE through recordings at
TFE concentrations of 27% and 23%, respectively. Spectra were processed with NMRPipe [36]
and evaluated with CCPNmr Analysis [37]. Analysis of Cα secondary chemical shifts is based
on the publication by Zhang et al. [38] and sequence corrected according to Schwarzinger [39].
Results
Secondary structure analysis by CD spectroscopy
TFE is known to induce α-helical structures by lowering the solvent polarity and promoting
intra-molecular hydrogen bonding [40]. Reducing the concentration of this co-solvent pre-
vents this effect e.g. as shown for Aβ(1–40) [41], human carbonic anhydrase II [42], FF domain
of URN1 splicing factor [43], transferrin [44], α-synuclein [45] and conalbumin [46]. The α-
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helices inducing effect of TFE on pEAβ(3–40) and the shift towards β-sheets by lowering the
TFE contents was analyzed by recording CD spectra in aqueous buffer in different TFE concen-
trations. CD spectra in solutions containing varying concentrations of TFE ranging from 25%
to 22% at pH 2.8 indicated a mainly α-helical conformation based on minima at 208 nm and
222 nm, a maximum at 193 nm and an x-axis intercept at 200 nm. Marginally loweringthe TFE
concentration from 22% to 20% or 21% was sufficient to alter the α-helical protein conforma-
tion of pEAβ(3–40) to a β-sheet dominated secondary structure (Fig 1a) as indicated by the
evolvement of characteristic β-sheet features in the corresponding CD spectra with a single
minimum at 216 nm, a x-axis intercept at 202 nm and a shift of the maximum to a lower wave-
length, i.e. 190 nm. CD spectra of Aβ(1–40) recorded under the same condition (20% TFE) dif-
fered compared to the spectra of pEAβ(3–40) by indicating α-helices (Fig 1b).
Aggregation kinetics and fibrillation
Aggregation analysis supported the CD data of pEAβ(3–40) and Aβ(1–40) indicating different
secondary structural elements in aqueous solution containing 20% TFE. Fig 2a displays the
aggregation kinetics in TFE containing solutions ranging from 20% to 25% TFE at 20°C for
pEAβ(3–40) as monitored by ThT assay. pEAβ(3–40) aggregation reaches its maximum at TFE
concentrations of 20% and 21%. A distinct lag phase of 9h (20% TFE) or 14 h (21% TFE) is
observable following a clear growth phase where aggregation increased indicating that β-sheet
formation is not hindered by the presence of TFE. In the presence of 25% TFE no THT fluores-
cence increase was observed during 72 h, which indicate that pEAβ(3–40) stays monomeric at
that condition. However, when the TFE concentration was lowered to 23% or 22% TFE a sig-
nificant delay as well as decreased maximum was detected within 72 h exploration time. Aggre-
gation of Aβ(1–40) could not be observed at all under the same conditions as no increase in
fluorescence intensity was detected within 72 h (Fig 2b). Thus, fibrillation and/or ThT positive
β-sheet formation of Aβ(1–40) seemed to be inhibited or at least significantly delayed in the
presence of the helix-stabilizing fluoroalcohol TFE.
Fig 1. Far-UV CD spectra of pEAβ(3–40) and Aβ(1–40). Peptides were dissolved in buffer (20–25% TFE in 50 mM potassium phosphate, pH 2.8). CD
spectra were recorded at 20°C from 260 to 187 nm, accumulated 10 times and background corrected. (a) CD spectra of 25 μM pEAβ(3–40) in 25%, 23%,
22%, 21% and 20% TFE showed a shift from α-helical structure towards β-sheets with decreasing TFE concentrations. (b) The CD spectrum of 25 μMAβ(1–
40) indicated α-helices in 20% TFE while the spectrum of 25 μM pEAβ(3–40) in 20% TFE showed mainly β-sheet rich structures.
doi:10.1371/journal.pone.0143647.g001
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TEMmicroscopy was performed to analyze the structure of pEAβ(3–40) aggregation prod-
ucts formed after incubation of the monomerized pepide in 20% TFE (Fig 3). pEAβ(3–40) built
large fibrils accumulating into aggregates with several μm in diameter. The fibrils were twisted,
exhibit a rather homogeneous morphology and accumulate into plaques comparable with
fibrils matured in aqueous solution [47].
NMR spectroscopy
Since pEAβ(3–40) started to aggregate at room temperature and built large fibrils in 20% TFE
(pH 2.8), 2D NMR spectroscopy was performed with only 25 μM recombinantly produced
[U-15N]-pEAβ(3–40). Nonetheless, considerably protein aggregation within 2 days even at the
low concentration applied impeded the recording of 3D experiments. To overcome this prob-
lem, backbone 1HN and
15N resonance assignments of pEAβ(3–40) in 20% TFE were obtained
by a time optimized BT-HNCA+ pulse sequence performed with pEAβ(3–40) in 30% TFE (S1
Fig). Transfer of the resonance assignments to the 1H,15N-HSQC spectrum in 20% TFE was per-
formed gradually from 30% through 27% and 23% TFE (S2 Fig). The Cα secondary chemical
shifts of pEAβ(3–40) in 30% TFE were neighbor-corrected and plotted as a function of the aa
sequence (S3 Fig). There is evidence that aa Y10-A21 and K28-V36 are involved in the α-helix
formation as indicated by positive secondary chemical shifts. This is in accordance with the sec-
ondary structure of pEAβ(3–40) in 40%TFE obtained from proton chemical shift data [29].
For reference, the spectrum of recombinant [U-15N]-Aβ(1–40) was acquired under identical
conditions and both 1H,15N-HSQC spectra were overlaid for comparison (Fig 4). The absence
of the first two amino acid residues D1 and A2 and the substitution of E3 to pE3 is the only dif-
ference between pEAβ(3–40) and Aβ(1–40). The main changes in chemical shifts are therefore
expected to be primarily observed for the very N-terminal amino acid residues. Interestingly,
signals of the N-terminal region up to E11 differed significantly (Fig 5). Cross-peaks further
Fig 2. Aggregation kinetics of pEAβ(3–40) and Aβ(1–40) in TFE. (a) 25 μM of monomerized pEAβ(3–40) were dissolved in buffer with various TFE
contents (25%, 23%, 22%, 21% and 20% TFE in 50 mM potassium phosphate, pH 2.8) including 10 μM ThT. pEAβ(3–40) aggregated in 20% and 21% TFE
but was significantly decreased in aqueous solution with higher TFE concentration. (b) 25 μM of monomerized pEAβ(3–40) and Aβ(1–40) were dissolved in
buffer (20% TFE in 50 mM potassium phosphate, pH 2.8) including 10 μM ThT. An increase in ThT fluorescence was observed for pEAβ(3–40) but not for Aβ
(1–40) within 72 h.
doi:10.1371/journal.pone.0143647.g002
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downstream towards the C-terminus, except of the C-terminal amino acid V40, were not or
only marginally changed.
Discussion
Previous data indicated that pyroglutamate-modified Aβ shows increased tendency to form β-
sheets compared to the unstructured Aβ in aqueous buffer at neutral pH [22, 48, 49]. Here, we
expand structural knowledge on pEAβ(3–40) by showing that it forms β-sheets even in the pres-
ence of considerably amounts of the co-solvent TFE. This is consistent with data indicating that
the tendency to build α-helical structures is decreased for pEAβ(3–40) as compared to unstruc-
tured Aβ(1–40) as analyzed by proton NMR spectroscopy at higher TFE concentrations, where
both peptides stay in monomeric conformation [29]. Our data indicate a change in conforma-
tion of pEAβ(3–40) as a result of lowering the TFE concentration. We identified the exact TFE
concentration (20% at pH 2.8) where pEAβ(3–40) already is in a β-sheet conformation, whereas
Aβ(1–40) exhibits still an overall α-helical conformation. This confirms, that TFE is not simply
favoring α-helical secondary structures, but secondary structures in general [50].
The differences in the secondary structure content observed by CD spectroscopy seem to be a
result of the modification from Aβ to pEAβ, which modifies the N-terminal region significantly.
ThT and TEM data support this evidence by yielding characteristic aggregation kinetics and
large matured fibrils for pEAβ(3–40) in 20% TFE but not for Aβ(1–40) under same conditions.
Using NMR spectroscopy, we analyzed pEAβ(3–40) monomers in 20% TFE (pH 2.8).
Under these conditions, pEAβ(3–40) slowly forms β-sheet containing aggregates that could not
be observed by solution NMR. Although it was shown in a model peptide starting with a N-ter-
minal E1 that conversion to pE1 results in altered chemical shifts only of the following two
amino acids [51], pE formation of Aβ peptides obviously affects not only the immediately
Fig 3. TEM image of pEAβ(3–40) in 50 mM potassium phosphate pH 2.8 containing 20% TFE.
Monomerized pEAβ(3–40) (25 μM) was incubated for fibrillation at 20°C for five days and grids were prepared
by negative staining. pEAβ(3–40) incubated in aqueous TFE solution formed large twisted fibrils up to several
hundred nm in size which accumulate into large aggregates ranging from 1–5 μm in diameter.
doi:10.1371/journal.pone.0143647.g003
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Fig 4. 1H,15N-HSQC of pEAβ(3–40) and Aβ(1–40). 25 μM of the monomerized peptides were dissolved in
aqueous solution (50 mM potassium phosphate, pH 2.8) containing 20% TFE. Spectra were recorded on a
600 MHz Bruker spectrometer at 5°C. Overlay of the spectrum of pEAβ(3–40) (red) and Aβ(1–40) (blue)
indicate that the pyroglutamate modification affects the N-terminal signals significantly towards E11 as well
as V40.
doi:10.1371/journal.pone.0143647.g004
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adjacent N-terminus. It was previously shown by HN and Hα proton chemical shift differences
between pEAβ(3–40) and Aβ(1–40) in higher TFE concentrations (40%), that mostly protons
of the six following amino acids from pE3 to S8 with decreasing influence towards the C-termi-
nus were affected [29]. In the presence of only 20% TFE, we observed many resonance differ-
ences of pEAβ(3–40) compared to Aβ(1–40). Chemical shift differences of the N-terminal
amino acids towards E11 as well as the C-terminal V40 were mostly affected as shown in Fig 5.
Thus, it seems that the modification of Aβ(1–40) to pEAβ(3–40) not only influence the neigh-
boring amino acids, but also change significantly the conformational state of at least 25% of all
amino acids. This result suggests that the N-terminal modification to pEAβ has a significant
effect on secondary structure elements and thus is the driving force for pEAβ(3–40) to be more
likely to build β-sheet structures under exactly the same conditions when compared to Aβ(1–
40). The propensity of pEAβ(3–40) to aggregate in aqueous TFE solution seems to be propa-
gated by the modified N-terminus, but V40 obviously play also a central role, maybe due to
interactions of both termini. Since C-terminally truncated Aβ peptides are less prone to aggre-
gation, e.g. Aβ(1–38)< Aβ(1–40)< Aβ(1–42) [52, 53], it is likely that their pE modified iso-
forms would show an increased aggregation propensity as compared to the non-pE-modified
isoforms, analogous to the results obtained within this study.
Supporting Information
S1 Fig. 15N-HSQC of pEAβ(3–40) in 30% TFE.
(TIF)
S2 Fig. 15N-HSQC of pEAβ(3–40) in different TFE concentrations.
(TIF)
S3 Fig. Cα secondary chemical shifts of pEAβ(3–40) in 30% TFE.
(TIF)
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